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Our aim was to identify the key proteins involved in the pathogenesis of AAAs. To explore the
possible pathogenetic mechanisms involved in AAA, we analyzed by proteomics modifications in
plasma proteome of patients with AAA. Therefore, the present study analyzed the soluble plasma
proteins using two dimensional electrophoresis (2-DE) and mass spectrometry (MS). We identified
33 protein spots, 31 of which show an up-regulation in AAA patients whilst the expression level
of 2 protein spots is reduced. We confirm a number of biomarkers associated with AAA that
have been previously identified by various authors. We identified a significant increase of a class
of proteins such as fibrinogen, a1-antitrypsin and haptoglobin in plasma from AAA patients. The
presence of these proteins in human AAA plasma may be related to the inflammatory processes
active in these subjects. We have seen a negative correlation between the vitamin D-binding
protein (DBP) and hemoglobin subunit b and AAA presence. DBP levels have been found to
increase in AAA wall tissues by others and this discrepancy with our results could be due to the
different analysis source. We wanted to analyze the factors measurable in plasma-associated
rather than in tissue-associated markers because the application of circulating biomarkers in
diagnostic laboratories would be relatively simple. DBP is very important for vascular
remodelling and it may have an important role in the protection of vascular walls. In plasma
tissue this protein reduces platelet aggregation and extends coagulation time. No one protein
identified in this study has the biologic plausibility to be used singularly as a biomarker of
aneurysmal disease due to inadequate specificity. The effect of using multiple biomarkers
combined with clinical factors requires investigation in carefully designed population-based
studies and these studies need to select the criteria of choice to define healthy controls very
carefully. Clearer identification of various markers is needed, possibly using other proteomic
techniques to screen for new candidates such as gel-free proteomic technology that enables us to
handle larger groups of subject compared to gel-based proteomic technology.
Introduction
Abdominal aortic aneurysm (AAA) affects 4%–8% of men
and 1.5% of women over age 60 years and usually remains
asymptomatic until rupture.1 AAA rupture is a medical
emergency with a mortality rate as high as 80%–90%,
40–50% of deaths occurring before reaching the hospital.
Because elective surgical repair has mortality rates less than
5%, great interest exists for population screening which is
currently based on ultrasonography (US), a highly accurate,
and noninvasive screening tool. However, although US
screening of men aged 65 or more can indeed reduce mortality
from ruptured AAA,2 a US based national screening programme
may also result in identifying a large number of patients unfit for
surgery but requiring a continued observation. Therefore, the
need for additional strategies to refine cost effectiveness of
screening programmes is currently advocated.3
A number of biomarkers associated with AAA presence
such as plasma fibrinogen, D-dimer, and IL-6 have now been
identified in cross-sectional case–control studies. Most studies
have not assessed the validity of these markers as diagnostic
tests for AAA because sensitivity and specificity appear to be
inadequate when hypothesizing the use of one single biomarker
for diagnosis.4 The effect of using multiple biomarkers
combined with clinical factors requires investigation in large,
carefully designed population-based studies. Proteomics has
been extensively employed to investigate cancer and other
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diseases, but there are currently no reports concerning the
proteomic study of plasma from patients affected by abdominal
aortic aneurysm. Very recently Urbonavicius et al. were the first
to identify proteins associated with the size of the AAA by
proteomic analysis of the vessel walls.5 They report positive
correlations between GAPDH, annexin A4, a fragment of trans-
forming growth factor-b-induced protein ig-h3 (TGFBIp)/b ig-h3
and the expansion of AAA. They also found a negative
correlation between apolipoprotein H, fibrinogen b chain,
ApoA-I and albumin and AAA size. Some protein spots were
of very low abundance or were ambiguously identified.
To explore the possible pathogenetic mechanisms involved
in AAA, we analyzed by proteomics modifications in plasma
proteome of patients undergoing aortic aneurysm repair.
Our aim was to identify the key proteins involved in the patho-
genesis of AAAs. Therefore, the present study analyzed the
soluble plasma proteins using two dimensional electrophoresis
(2-DE) and mass spectrometry (MS). We identified 33 protein
spots, 31 of which show an up-regulation in AAA patients
whilst the expression level of 2 protein spots is reduced.
Materials and methods
Subjects investigated
Plasma from 8 patients scheduled for abdominal aortic aneurysm
(AAA) repair through elective aortic reconstructive surgery
was investigated. The control group included 6 age-matched
volunteers. Exclusion criteria were diabetes, evidence of peri-
pheral vascular disease, recent history of myocardial infarction,
chronic intestinal inflammatory disease, widespread cancer,
left ventricular ejection fraction inferior to 40%, symptomatic
congestive heart failure, significant segmental wall motion
abnormalities prior to dobutamine stress echocardiography,
new wall motion abnormalities detected during dobutamine
stress echocardiography and inability to understand informed
consent. Experimental protocols were approved by the local
Ethical Committee and written consent was obtained from each
enrolled subject.
Experimental protocol
Venous blood samples (2 ml) were collected in K2EDTA-
containing tubes on the day of their admission to General
Hospital. Blood was centrifuged at 4 1C, 1000 g for 10 min,
and the isolated plasma samples were stored at80 1C until use.
Protein concentration of each sample was determined by the
standard Bradford method (Bio-Rad).
Two-dimensional electrophoresis
An aliquot of 6.25 ml of plasma was mixed with 10 ml of a
solution containing 10% (w/v) sodium dodecyl sulfate (SDS)
and 2.3% (w/v) dithioerythritol (DTE). The sample was
heated to 95 1C for 5 min and then diluted to 500 ml with a
solution containing 8 M urea, 4% (w/v) 3-cholamidopropyl
dimethylammonium-1-propane sulfonate (CHAPS), 40 mM
Tris, 65 mM DTE.6 Isoelectric focusing (first dimension) was
carried out on nonlinear wide-range immobilized pH gradients
(IPGs; pH 3.0–10 NL; 18 cm-long IPG strips; GE Healthcare,
Uppsala, Sweden) and achieved using an EttanTM IPGphort
system (GE Healthcare, Uppsala, Sweden). IPG strips were
rehydrated with 60 mg of the plasma sample for analytical run,
and with 400 mg of plasma for preparative-run, diluted in
350 ml of rehydration buffer containing 8 M urea, 4% (w/v)
CHAPS, 65 mMDTE, and 0.5% IPG buffer with the same pH
range as the Immobiline DryStrips and a trace of bromo-
phenol blue, for 1 h at 0 V and for 8 h at 30 V, at 20 1C.
The strips were focused according to the following electrical
conditions at 16 1C: 200 V for 1 h, from 300 to 3500 V in
30 min, 3500 V for 3 h, from 3500 to 8000 V in 30 min, and
8000 V until a total of 80 000 V per h was reached. After
isoelectric focusing separation, the strips were equilibrated
with 10 ml of a solution containing 50 mM Tris-HCl pH 6.8,
6 M urea, 30% (v/v) glycerol, 2% (w/v) SDS, and 2% (w/v)
DTE for 12 min and with 10 ml of a solution containing
50 mM Tris-HCl pH 6.8, 6 M urea, 30% (v/v) glycerol, 2% (w/v)
SDS, 2.5% (w/v) iodoacetamide and a trace of bromophenol blue
for 12 min. The second dimension was carried out on 9–16%
polyacrylamide linear gradient gels (18 cm 20 cm 1.5 mm) at
10 1C and 40 mA per gel constant current until the dye front
reached the bottom of the gel. Analytical gels were stained with
ammoniacal silver nitrate.7 The exposure time for silver staining
was optimized to avoid overexposure of some gels in comparison
to others. The mass spectrometry preparative gels were stained
with colloidal Coomassie blue G-250 (Sigma-Aldrich).
Image analysis and statistics
Two-DE images were scanned by using the Epson expression
1680 PRO scanner. For each investigated subject, three technical
replicates were performed and only spots present in all the
replicates were taken into consideration for subsequent analysis.
A cut-off limit was considered to limit interference due to
individual physiological changes, in particular each spot
intensity volume was processed by background subtraction
and then normalized between gels as a proportion of total
protein intensity from entire gel using ImageMaster 2D
Platinum 6.0 software (GE Healthcare). Relative spot volume
(%V) (Vsingle spot/Vtotal spots, where V is the integration of the
optical density over the spot area) was used for quantitative
analysis in order to decrease experimental errors. The mean
values of the %V were compared among the two groups
(AAA patients and age-matched volunteers) by Student’s
t-test analysis of variance (ANOVA) and by non-parametric
Wilcoxon rank-sum test (for continuous variable), using the
Graphpad Prism4 software. The spots selection criteria for MS
were: (1) fold-change to select differentially expressed protein
spots. Regarding the error range of spot detection which is
determined by evaluating the reproducibility of 2-DE gels, we set
the threshold at Z2-fold change for considering a protein spot
differentially expressed (a variation of the mean %V of above
2-fold among the two groups); (2) p-value r 0.05 to select
differentially expressed protein spots that displayed a statistically
significant variation of the mean %V among the two groups.
p-value was calculated by Student’s t-test and by non-parametric
Wilcoxon rank-sum test (for continuous variable), using the
Graphpad Prism4 software. Only the differentially expressed
protein spots with a threshold of Z 2-fold change and with a
p-value r 0.05 were selected for mass spectrometry analysis.
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Protein identification by MALDI-TOF mass spectrometry
Protein identification was carried out by peptide mass
fingerprinting on an Ettan matrix-assisted laser desorption/
ionization (MALDI) time-of-flight (TOF) Pro mass spectro-
meter (Amersham Biosciences), as previously described.8,9
Electrophoretic spots, visualized by the colloidal Coomassie
staining protocol, were manually excised, destained, and aceto-
nitrile dehydrated. Successively, they were rehydrated in trypsin
solution and in-gel protein digestion was performed by an
overnight incubation at 37 1C. From each excised spot,
0.75 ml of recovered digested peptides were prepared for
MALDI-TOF MS by spotting them onto the MALDI target,
allowing them to dry and then mixing them with 0.75 ml of
matrix solution (saturated solution of a-cyano-4-hydroxy-
cinnamic acid in 50% (v/v) acetonitrile and 0.5% (v/v) trifluoro-
acetic acid). After application of the matrix to the dried sample
and drying, tryptic peptide masses were acquired. Protein
identification by Peptide Mass Fingerprints search was per-
formed using MASCOT version 2.2 as the search engine
(Matrix Science, London, UK, http://www.matrixscience.com)
through the Swiss-Prot/UniprotKB database, release 57.11,
24 November 2009.
Protein identification was achieved on the basis of corres-
ponding experimental and theoretical peptide-fingerprinting
patterns. Search parameters were: peptide mass tolerance of
100 ppm; a single trypsin missed cleavage; alkylation of
cysteine by carbamidomethylation as fixed modification, and
oxidation of methionine as variable modification. The query
was first opened to the entire database in order to highlight
any artifactual identification and after that restricted to
human proteins. The criteria used to accept identifications
included the extent of sequence coverage, the number of
matched peptides, and the probabilistic score obtained by
using Mascot software, as reported in Table 3. In detail,
the identifications were accepted as positive when at least
4 matching peptides and at least 10% peptide coverage of
theoretical sequences matched, setting the probabilistic score
at p o 0.05. Regarding the probabilistic score, the threshold
Mascot MS protein score greater than 56 was considered
significant (p-value o 0.05). (The Mascot score is 10log (P),
where P is the probability that the observed match is a random
event.) Tryptic digests that did not produce MALDI-TOF
unambiguous identifications were subsequently acidified with
2 ml of a 1% trifluoroacetic acid solution, and then subjected
to electrospray ionization (ESI) ion trap MS/MS peptide
sequencing using an LCQ DECA ion trap mass spectrometer
(Thermo Finnigan, San Jose, CA, USA). Acidified samples
were enriched using ZIP-TIPTM pipette tips for sample
preparation (Millipore, Billerica, MA, USA), previously equili-
brated in 50% acetonitrile solution and abundantly washed
in 0.1% trifluoroacetic acid. Tryptic peptide elution from the
ZIP-TIPTM matrix was achieved with a 70% methanol and
0.5% formic acid solution; and 3 ml of concentrated sample
solution was then loaded into the nanospray needle. MS/MS
database searching was performed by Mascot MS/MS ion
search software (http://www.matrixscience.com) in the Swiss-
Prot/UniprotKB database (release 57.11, 24 November 2009).
The following criteria were applied: MS accuracy 1.2 Da,
MS/MS mass accuracy 0.6 Da, peptide precursor charge 2+,
monoisotopic experimental mass values, trypsin digestion with
one allowed missed cleavage, fixed carbamidomethylation of
cysteine and variable oxidation of methionine. The probabilistic
score for the LC-MS/MS analysis was obtained using Mascot
software. The Mascot individual ions score greater than 35
was considered significant (p-value o 0.05). (Ions score is
10log (P), where P is the probability that the observed match
is a random event.)
Results
Subjects
Table 1 summarizes the clinical characteristics of the eight
AAA patients and the six control subjects enrolled for the
present study. The patients were on waiting list for elective
aortic reconstructive surgery. The overall mean age of the
AAA group and the age-matched control group is 65.6  6.9.
However the age of AAA patients was slightly higher than that
of the control group. Values of smoking, blood pressure and
heart rate were higher among patients with AAA. No other
cardiovascular risk factors differed between the groups.
No patients received cardiovascular drugs or other support
of cardiac function during the observation period. The
anthropometric parameters did not differ between the two
types of subjects.
Plasma protein profiles of AAA and control subjects
Protein profiles of plasma samples from eight patients
with abdominal aortic aneurysm (AAA) and from six healthy
controls were analyzed by 2-DE. For each investigated subject,
plasma proteins were separated by 2-DE gel and the resulting
silver-stained gels were analyzed using ImageMaster 2D
Platinum version 6.0 (GE Healthcare). To obtain statistically
significant results, each plasma protein sample was run in
triplicate. Relative spot volume (%V) (Vsingle spot/Vtotal spots,
where V is the integration of the optical density over the spot
area) was used for quantitative analysis in order to decrease
experimental errors. The circulation half-life of low molecular
weight plasma proteins is directly related to their binding
affinity to high abundant carrier proteins.10,11 This observa-
tion has been supported by proteomic based studies that have
detected a significant amount of low molecular weight proteins
in specific carrier protein fractions (serum albumin).12 To
avoid an alteration of proteomic results we decided not to
remove highly abundant proteins such as albumin and IgG.
Table 1 Clinical characteristics of the investigated groups
Abdominal aortic
aneurysm group
(n = 8)
Age-matched
control group
(n = 6)
Male/female 6/2 6
Age, years 68  6 62  7
Weight, kg 72  8 68  11
Height, cm 170  5 176  6
Systolic blood pressure, mmHg 128  9 100  12
Diastolic blood pressure, mmHg 78  10 70  5
Heart rate, beats per min 71  10 68  8
Smokers (n) 6 2
2858 Mol. BioSyst., 2011, 7, 2855–2862 This journal is c The Royal Society of Chemistry 2011
This would cause the removal of a broad range of other low
mass and low abundant physiologically important regulatory
and/or transient proteins.13 Fig. 1 shows a representative two
dimensional gel image of AAA plasma (panel A) and of
control plasma (panel B). Approximately 900 spots in each
silver nitrate-stained gel, ranging from 10 to 200 kDa with a
pH between 3 and 10, can be visualized by ImageMaster
software. When the 2-DE gels of plasma proteins from the
patients were compared with those from healthy controls,
many chains of spots that may represent different degrees
of protein post-translational modifications (PTMs) and/or
different isoforms of the same protein were found to be
significantly over-expressed. When gels corresponding to the
plasma proteins from the healthy subjects were used as
reference in 2-DE gel analysis, the densities of 33 protein spots
were found to be changed in the gels corresponding to plasma
proteins from AAA patients.
Identification of differentially expressed proteins
The comparative analysis revealed that in AAA patients 33
protein spots were differentially expressed by approximately
Z 2-fold change and with a p-value r 0.05. The locations of
these 33 differentially expressed protein spots are marked with
arrows and numbers in the representative gels shown in Fig. 1.
Of these spots, 31 were up-regulated and 2 down-regulated
in comparison to the healthy subjects. A list of the up- and
down-regulated proteins as well as their biological functions
according to their Gene Ontology (GO) biological process
is summarized in Tables 2 and 3. Table 2 reports all the
identified proteins, their relative amounts expressed as the
mean  standard deviation of the relative spot volume (%V)
(Vsingle spot/Vtotal spots, where V is the integration of the optical
density over the spot area) and statistical analysis (fold
change Z 2 and p-value o 0.05). A group of 4 protein spots
(7, 15, 18 and 23) show a significant increase using the
ANOVA test (see Table 3), in contrast they show a non-
significant increase (p-values: 0.0526, 0.0704, 0.0593 and
0.0810 respectively) using the non-parametric Wilcoxon test.
Despite this discrepancy these 33 differentially expressed pro-
tein spots were excised from preparative Coomassie-stained
2-DE gels, in-gel digested with trypsin, and subsequently
analyzed by MS. All identified proteins are described in
Table 3. As shown in the table the sequence coverage (number
of the identified residues/total number of amino acid residues
in the protein sequence) of the proteins identified, by peptide
mass fingerprinting, ranges from 12% to 72%, depending on
the size and amount of each protein. The identification of
protein spot 21 with low protein quantity was further con-
firmed by electrospray ionization (ESI)–ion trap MS/MS
peptide sequencing, the relative results are reported in
Table 3. It is known that plasma proteins are affected by
post-translational modifications. Among the 33 protein spots
we found several isoforms of nine proteins (a1-antitrypsin,
complement factor B, serotransferrin, fibrinogen a chain, fibri-
nogen g chain, hemopexin, haptoglobin a chain, haptoglobin
b chain, ApoJ) that differed in the molecular weight and/or in
the pI (values reported in Table 3). These modifications could be
due to protein degradation or to post-translational modifications
such as glycosylation, phosphorylation, oxidation, disulfide
bond formation. Using Mascot research we explored the
presence of such PTMs. We obtained results with a significant
Mascot MS score for all proteins using oxidation of methionine
as variable modification in the research parameter. For example
a1-antitrypsin (spot 2) was more oxidised than spot 1 (5 residues
instead of 1); fibrinogen a chain, spots 10, 11, 12 differ also in
oxidation rate; apolipoprotein J, spot 27 is oxidised unlike spot 28.
Moreover as reported by Chalkley R.J. et al.14 there are some
flaws in the current search engines software used for PTMs:
they mostly apply an intensity threshold to the peak list to limit
‘noise peaks’ and this can eliminate peaks that contain basal
Fig. 1 Representative silver-stained gels of plasma proteins. Arrows and numbers indicate protein spots identified by MS. (A) Representative
2-DE gel of AAA plasma. (B) Representative 2-DE gel of control subject plasma.
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information regarding the localization process, moreover they
do not clearly indicate site assignment reliability i.e. they ignore
the ambiguity issue. In most cases, the solution is the manual
verification and this introduces a wide range of variability in the
results. Studies show that inflammation with infiltrates of macro-
phages and lymphocytes is an important feature of AAA.15,16
Indeed, several of the proteins whose expression increased
in AAA patients were proteins involved in the acute phase.
Moreover, in patients with AAA, elevated levels of various
plasma markers of inflammation have been reported. Among
these proteins we identified extracellular matrix proteins: three
different isoforms of fibrinogen a chain (spots 10, 11, 12) and two
isoforms of fibrinogen g chain (spots 16 and 18).
Fibrinogen is an essential glycoprotein since it is a precursor
to fibrin. It is formed by three different chains a, b, and g and
increases the aggregation of platelets, endothelial cells, and
leukocytes. This aggregation is responsible for leukocyte
and platelet activation leading to cell release of mediators.
Plasma fibrinogen concentrations have been reported by
Al-Barjas to correlate positively with AAA.17 As previously
reported13 in AAA patients high levels of fibrinogen are
associated with fibrin degradation products such as D-dimer
which has multiple pro-inflammatory effects. Fibrin degrada-
tion may mediate the observed increase of acute phase reac-
tants in AAA pathogenesis.18 We identified three isoforms of
Complement Factor B (spots 4, 5, 6), this protein is part of the
alternative pathway of the complement system which plays
a central role in innate immunity and participates in auto-
immunity, debris removal and response to tissue injury as it can
operate without antibody participation. Although the literature
on the role of the complement system in human AAA is scant,
studies on mice with AAA disease present evidence that the
classic and alternative pathways of the complement system are
activated in AAA tissues. The authors formulated the hypo-
thesis that the complement system participates in the develop-
ment of AAA by providing the necessary chemotactic signal
that attracts neutrophils to the aortic wall.19
Complement Factor B circulates in the blood as a single
chain polypeptide producing the catalytic subunit Bb, a serine
protease that associates with the C3b-fragment to form the
alternative C3 convertase pathway. To date, few reports have
described the deposition of C3 and antibodies in human AAA
tissues.20 Our data strengthen the hypothesis of a relationship
between human AAA and the complement system. Among the
Table 2 Quantitative data and statistical analyses of protein spots whose intensity levels significantly differed among plasma of patients with
AAA and age-matched control group
Spot
Average spot volume% in AAA patients
(arbitrary units)a
Average spot volume% in age-matched control
group (arbitrary units)a
Volume ratio
(AAA/control group)
ANOVA
(p value)b
Wilcoxon
(p value)cMean SD Mean SD
1 0.1311 0.0526 0.0619 0.0294 2 0.0138 0.0127
2 0.1159 0.0510 0.0542 0.0277 2 0.0205 0.02
3 0.0716 0.0375 0.0259 0.0087 2.8 0.0131 0.0007
4 0.0718 0.0404 0.0234 0.0079 3 0.0141 0.02
5 0.1448 0.0896 0.0577 0.0299 2.5 0.0427 0.028
6 0.0908 0.0461 0.0342 0.0239 2.6 0.0186 0.0008
7 0.1253 0.0668 0.0418 0.0191 3 0.0122 0.0526d
8 0.2467 0.0988 0.1025 0.0301 2.4 0.0050 0.02
9 0.4741 0.1389 0.2124 0.0744 2.2 0.0013 0.0007
10 0.5053 0.2235 0.2487 0.1021 2 0.0234 0.033
11 0.1138 0.0499 0.0374 0.0198 3 0.0042 0.0036
12 0.0920 0.0300 0.0439 0.0298 2 0.0115 0.02
13 0.0380 0.0165 0.0136 0.0054 2.8 0.0047 0.0055
14 0.3056 0.1918 0.1103 0.0490 2.8 0.0328 0.0127
15 0.7965 0.5520 0.1507 0.0842 5 0.0157 0.0704d
16 0.1141 0.0616 0.0348 0.0176 3.2 0.0104 0.0117
17 0.1242 0.0754 0.4092 0.2643 3.3 0.0126 0.0278
18 0.1633 0.0910 0.0724 0.0290 2.2 0.0375 0.0593d
19 0.1129 0.0413 0.0520 0.0447 2.2 0.0217 0.0167
20 0.0560 0.0245 0.0266 0.0090 2 0.0167 0.02
21 0.0253 0.0105 0.0089 0.0042 2.8 0.0036 0.0047
22 0.8825 0.4315 0.3820 0.1890 2.3 0.0217 0.0168
23 0.4240 0.1253 0.2100 0.1872 2 0.0245 0.0810d
24 0.5385 0.2086 0.1932 0.0865 2.8 0.0026 0.0066
25 0.3655 0.1470 0.1115 0.0393 3.3 0.0015 0.0081
26 0.0892 0.0369 0.0427 0.0061 2 0.0104 0.0024
27 0.0559 0.0191 0.0257 0.0132 2.2 0.0063 0.02
28 0.2375 0.1306 0.0538 0.0151 4.4 0.0053 0.007
29 0.0515 0.0213 0.0204 0.0135 2.5 0.0088 0.0117
30 1.2734 0.7087 0.0927 0.0426 13 0.0017 0.0007
31 1.5263 0.6779 0.5537 0.2059 2.7 0.0056 0.0027
32 0.4484 0.1623 0.2233 0.0924 2 0.0105 0.0233
33 0.4299 0.2330 1.1583 0.4739 2.7 0.0025 0.0013
a The volume percentage (%V) is calculated as Vsingle spot/Vtotal spots (V is the integration of the optical density over the spot area) using ImageMaster
2D platinum 6.0 software (GE Healthcare). b p-value calculated group by analysis of variance (ANOVA). c p-value calculated group by the non-
parametric test (Wilcoxon rank-sum) using the GraphPad Prism4 software. p r 0.05 was considered statistically significant. d See Results.
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acute phase proteins over-expressed in AAA patients we found
five isoforms of haptoglobin b chain (spots 22, 23, 24, 25 and
26) and three isoforms of haptoglobin a chain (spots 30, 31
and 32). This protein is one of the major plasma glycoproteins
and its levels often increase during inflammation, tissue
damage and diseases such as cancer and arthritis.21 It is
composed of a and b polypeptide chains that are covalently
associated by disulfide bonds. Many authors suggested that
a and b polypeptides are synthesized via a common precursor
polypeptide.22 Haptoglobin is a positive acute phase protein
that binds free hemoglobin and removes it from blood circula-
tion to prevent kidney injury and iron loss following hemo-
lysis. Also, by binding free hemoglobin, haptoglobin acts as a
potent antioxidant and an immunosuppressor of lympho-
cyte function.23 Indeed, in correlation with this, we found a
reduced level of hemoglobin subunit b (spot 33) in plasma of
AAA patients. This reduced level of hemoglobin in plasma
from AAA patients could be related to the increased level of
haptoglobin which is responsible for the hemoglobin removal
from the plasma of these subjects.
We identify other acute phase proteins such as a2-HS-
glycoprotein (spot 14), a1-antitrypsin (spots 1, 2 and 15),
a2-macroglobulin (spot 3 protein fragment) and leucine-rich
glycoprotein (spot 21) as up-regulated in AAA patients,
thus suggesting a generalized pro-inflammatory state in these
subjects. The protein a1-antitrypsin is an inhibitor of serine
Table 3 Matrix-assisted laser desorption/ionization time of flight (MALDI-TOF) mass spectrometry (MS) and MS/MS analyses of proteins
whose levels significantly differed among patients with AAA and age-matched control group
Spot Protein name
Swiss-Prot
entrya Biological functionb
MALDI-TOF MS
Predicted
pI/Mrf
(kDa)
Exp. pI/Mrg
(kDa)Scorec
Seq. cov.d
(%)
No. of matched
massese
1 a1-Antitrypsin P01009 Protease inhibitor 145 32 11 5.37/46.88 5.05/131.36
2 a1-Antitrypsin P01009 Protease inhibitor 231 48 18 5.37/46.88 5.00/132.63
3 a2-Macroglobulin (fragment) P01023 Protease inhibitor 128 12 13 6.00/164.61 5.54/134.35
4 Complement factor B P00751 Complement fraction 130 20 10 6.67/86.85 6.41/111.05
5 Complement factor B P00751 Complement fraction 108 18 9 6.67/86.85 6.50/111.87
6 Complement factor B P00751 Complement fraction 170 31 15 6.67/86.85 6.60/111.87
7 Serotransferrin P02787 Ion transport 232 32 21 6.81/79.28 6.59/99.01
8 Serotransferrin P02787 Iron ion transport 144 30 17 6.81/79.28 6.50/95.26
9 Serotransferrin P02787 Iron ion transport 315 43 27 6.81/79.28 6.68/95.26
10 Fibrinogen a chain P02671 Coagulation factor 186 21 21 5.70/95.66 7.07/81.64
11 Fibrinogen a chain P02671 Coagulation factor 174 23 20 5.70/95.66 7.33/80.72
12 Fibrinogen a chain P02671 Coagulation factor 160 20 20 5.70/95.66 7.15/81.64
13 Kininogen-1 (fragment) P01042 Coagulation factor 101 18 10 6.34/73.00 5.01/80.46
14 a2-HS-glycoprotein P02765 Protease inhibitor 117 28 9 5.43/40.10 4.62/72.71
15 a1-Antitrypsin P01009 Protease inhibitor 218 48 18 5.37/46.88 4.90/72.36
16 Fibrinogen g chain P02679 Coagulation factor 243 60 18 5.37/52.11 5.15/64.44
17 Vitamin D-binding protein P02774 Transport protein 204 46 16 5.40/54.53 5.28/68.95
18 Fibrinogen g chain P02679 Coagulation factor 132 34 11 5.37/52.11 5.25/63.82
19 Hemopexin P02790 Transport protein 168 32 13 6.55/52.39 4.98/51.94
20 Hemopexin P02790 Transport protein 132 29 12 6.55/52.39 6.72/56.79
21 Leucine-rich a2-glycoprotein P02750 Hemostasis DLLLPQPDLRh 6.45/38.38 4.66/56.60
22 Haptoglobin (b chain) P00738 Hemoglobin binding
protein
127 24 11 6.13/45.86 4.89/52.79
23 Haptoglobin (b chain) P00738 Hemoglobin binding
protein
121 25 11 6.13/45.86 5.35/43.88
24 Haptoglobin (b chain) P00738 Hemoglobin binding
protein
107 25 11 6.13/45.86 5.57/42.90
25 Haptoglobin (b chain) P00738 Hemoglobin binding
protein
111 27 10 6.13/45.86 5.81/46.21
26 Haptoglobin (b chain) P00738 Hemoglobin binding
protein
105 21 10 6.13/45.86 5.99/44.81
27 Apolipoprotein J P10909 Transport protein 144 27 9 5.89/53.03 4.90/41.75
28 Apolipoprotein J P10909 Transport protein 101 21 7 5.89/53.03 4.98/40.30
29 Apolipoprotein A-I P02647 Transport protein 208 50 15 5.56/30.76 5.17/31.84
30 Haptoglobin (a chain)
(fragment)
P00738 Hemoglobin binding
protein
74 15 5 6.13/45.86 5.41/16.08
31 Haptoglobin (a chain) P00738 Hemoglobin binding
protein
53 17 5 6.13/45.86 5.81/15.93
32 Haptoglobin (a chain) P00738 Hemoglobin binding
protein
68 17 8 6.13/45.86 6.34/15.51
33 Hemoglobin subunit b P68871 Transport protein 157 72 8 6.75/16.10 7.12/9.83
a SwissProt/UniprotKB accession number. b Biological function of the identified proteins according to their Gene Ontology (GO) biological
process. c MASCOT MS score (Matrix Science, London, UK; http://www.matrixscience.com). MS matching score greater than 56 was required
for a significant MS hit (p-value o 0.05). d Sequence coverage = (number of the identified residues/total number of amino acid residues in the
protein sequence)  100%. e Number of peptide masses matching the top hit from Ms-Fit PMF. f Predicted pI and Mr according to protein
sequence. g Experimental pI and Mr based on the calculation using software ImageMaster 2D Platinum 6.0 (GE Healthcare). h Sequence tag
identified by ESI-Ion trap MS/MS peptide-sequencing with Mascot MS/MS score: 53. The Mascot individual ions score greater than 35 was
considered significant (p-value o 0.05).
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proteases. Its primary target is the protein elastase, but it
also has a moderate affinity for plasmin and thrombin. It
irreversibly inhibits trypsin, chymotrypsin and plasminogen
activator. Even though the physiological function of leucine
rich glycoprotein is still unknown, changes in the concentra-
tions of this protein were identified by Bini et al. using 2-DE
in human serum during bacterial infection and in serum of
patients with meningitis.24 Among the acute phase proteins we
identify hemopexin (spots 19 and 20), a glycoprotein released
into plasma where it binds heme with high affinity. The better
characterized function of hemopexin is heme scavenging at the
systemic level by transporting heme to the liver. This is
important both in physiologic heme management for heme–
iron recycling and in pathologic conditions associated with
intravascular hemolysis to prevent the pro-oxidant and
pro-inflammatory effects of heme. Hemopexin is not only a
systemic scavenger for heme but also acts as a multifunctional
agent in important processes such as iron homeostasis,
antioxidant protection, pathway signalling to promote cell
survival and gene expression.25 We found another binding
transport protein which can bind iron: three isoforms of
serotransferrin (spots 7, 8 and 9). This protein is responsible
for the transport of iron from sites of absorption and heme
degradation to those of storage and utilization. Serotransferrin
may also have a role in stimulating cell proliferation and acute
phase response.26
We found two up-regulated apolipoproteins in AAA patients:
two isoforms of ApoJ (clusterin: spots 27 and 28) and ApoA-1
(spot 29). Recently van Dijk and colleagues have shown a
protective effect of exogenous ApoJ in vitro on ischaemically
altered cardiomyocytes. They hypothesized that ApoJ is
involved in reducing infarction damage.27 Other authors have
reported that ApoJ mRNA was expressed in smooth muscle
cells after vascular injury, suggesting that ApoJ contributes to
restenosis post-angioplasty.28 Even though AAA and athero-
sclerosis have many risk factors in common, studies investi-
gating the association between lipids/lipoproteins and AAA
have provided different results.29
Only a limited number of studies have explored apolipo-
protein concentration in relation to AAA. In a population-
based study of AAA the plasma levels of apoA-1 were found
to be decreased in AAA patients in comparison to those in
healthy subjects; this decrease was independently correlated
with the reduced levels of other apolipoproteins.30 ApoA-1 is
the primary protein constituent of high-density lipoproteins
(HDL). Low circulating levels of HDL is a risk factor for
cardiovascular diseases and is associated with arterial endo-
thelium dysfunction. In this study, both proteins ApoA-1 and
ApoJ are positively associated with AAA. An increasing
number of studies demonstrate that lipoprotein concentrations
in subjects with AAA are higher than that in healthy control
subjects yet correspond to that found in patients with
atherothrombosis.
The relation between lipoproteins and AAA progression is
currently unclear and a clearer identification of such correla-
tion is needed, possibly using proteomic techniques.
The few protein spots whose levels are reduced in the AAA
patients in comparison to the healthy controls were vitamin
D-binding protein (spot 17) and hemoglobin subunit b (spot 33).
The vitamin D-binding protein (DBP) is the major plasma
carrier protein of vitamin D and its metabolites. This protein is
of potential importance for vascular remodelling and may
contribute to an observed protective role of vitamin-D
sterols in vascular diseases development. Urbonavicius and
collaborators5 were the first to find that, by proteomic
approach analyzing vascular walls, this protein is positively
correlated with the size of AAA. However, regarding the
up-regulation of DBP expression levels, the authors reported
that a collagen fragment was identified in the DBP spot. For
this reason they could not accurately establish if its expression
levels increased in AAA patients. In our experimental condi-
tions we encountered a completely different behaviour of the
DBP expression level in AAA patients. As reported in Table 2
the protein (spot 17) shows an evident decrease in expression
in comparison to the control (volume ratio AAA/control
group = 3.3). Further studies are required to confirm the
potential and clinical role of DBP in this human disease and to
further investigate whether and how this protein participates
in the pathogenesis of the disease.
Discussion
Using a proteomic approach we identified a significant
increase of a class of proteins such as fibrinogen, a1-antitrypsin
and haptoglobin in plasma from AAA patients. The presence of
these proteins in human AAA plasma may be related to the
inflammatory processes active in these subjects. We have seen a
negative correlation between the vitamin D-binding protein and
hemoglobin subunit b and AAA presence. DBP levels have
been found to increase in AAA wall tissues by Urbonavicius
et al. and this discrepancy with our results could be due to
the different analysis source. We wanted to analyze the
factors measurable in plasma-associated rather than in tissue-
associated markers because the application of circulating bio-
markers in diagnostic laboratories would be relatively simple.
DBP is very important for vascular remodelling and it may have
an important role in the protection of vascular walls. In plasma
tissue this protein reduces platelet aggregation and extends
coagulation time.
Furthermore, only proteins whose quantity exceed approxi-
mately 3 ng and with a molecular mass between 10 and
200 kDa are detected by the 2-DE technique. Proteins in very
low abundance are extremely difficult to identify using this
gel-based proteomic technique. The present work is merely an
example of the use of 2-DE andMS to identify several proteins
at a given time in plasma of patients with AAA. Thus, further
studies are needed to firmly establish which specific proteins or
fragments participate in this disease’s development.
In conclusion, in this study we confirm a number of bio-
markers associated with AAA that have been previously
identified by various authors. No one protein identified in this
study has the biologic plausibility to be used singularly as a
biomarker for aneurysmal disease due to inadequate specifi-
city. The effect of using multiple biomarkers combined with
clinical factors requires investigation in carefully designed
population-based studies and these studies need to select the
criteria of choice to define healthy controls very carefully.
Clearer identification of various markers is needed, possibly
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using other proteomic techniques such as gel-free proteomic
methodologies to screen for new candidates.
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